Connor, Clark & Lunn Investment Management Ltd. Allakos Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 05, 2022	BUY	$2.6 - $6.14 $13,829 - $32,658	5,319 Added 3.12%	176,070 $551,000
Q1 2022 May 12, 2022	BUY	$5.08 - $9.81 $867,415 - $1.68 Million	170,751 New	170,751 $973,000

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

Bvf Inc San Francisco, CA

16.6M
Shares

$17.5 Million
0.34% of portfolio
Nea Management Company, LLC Timonium, MD

6.15M
Shares

$6.52 Million
0.31% of portfolio
Deep Track Capital, LP Greenwich, CT

5M
Shares

$5.3 Million
0.12% of portfolio
Vanguard Group Inc Valley Forge, PA

3.51M
Shares

$3.73 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

3.08M
Shares

$3.26 Million
0.13% of portfolio

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account